International Journal of Hematology

, Volume 95, Issue 5, pp 516–526

Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma

  • Miki Kiyota
  • Tsutomu Kobayashi
  • Shinichi Fuchida
  • Mio Yamamoto-Sugitani
  • Muneo Ohshiro
  • Yuji Shimura
  • Shinsuke Mizutani
  • Hisao Nagoshi
  • Nana Sasaki
  • Ryuko Nakayama
  • Yoshiaki Chinen
  • Natsumi Sakamoto
  • Hitoji Uchiyama
  • Yosuke Matsumoto
  • Shigeo Horiike
  • Chihiro Shimazaki
  • Junya Kuroda
  • Masafumi Taniwaki
Original Article

DOI: 10.1007/s12185-012-1035-8

Cite this article as:
Kiyota, M., Kobayashi, T., Fuchida, S. et al. Int J Hematol (2012) 95: 516. doi:10.1007/s12185-012-1035-8

Abstract

We retrospectively investigated the prognostic impact of high-risk cytogenetic abnormalities (CAs) on the outcome of treatment with bortezomib plus dexamethasone (BD) in 43 relapsed/refractory (Rel/Ref) multiple myeloma patients. Fluorescence in situ hybridization (FISH) analysis identified del(13q) in 25 patients, t(4;14) in 14, t(14;16) in 4, 1q21 abnormality in 12 and del(17p) in 2, while G-banding also detected chromosome 13 monosomy (−13) in metaphase spreads from 7 patients. Eighteen of 25 patients with FISH-detected chromosome 13 abnormalities also exhibited other abnormalities. Median observation period was 510 days, and median overall survival (OS) and progression-free survival (PFS) were 912 days and 162 days, respectively. Detection of del(13q), t(4;14), t(14;16) or 1q21 abnormalities by FISH and co-occurrence of chromosome 13 abnormality with other abnormalities were not associated with poorer outcomes. In contrast, detection of −13 by G-banding in metaphase spreads showed significant association with shorter OS, although the overall response rate and PFS were not inferior to those for patients without −13 detected by G-banding. BD therapy may be a potent weapon for overcoming most classical high-risk CAs, while the detection of −13 in metaphase spreads may serve as a predictor of highly progressive disease, even when treated with BD.

Keywords

Bortezomib Multiple myeloma Chromosome 13 abnormalities Metaphase spreads Prognosis 

Copyright information

© The Japanese Society of Hematology 2012

Authors and Affiliations

  • Miki Kiyota
    • 1
  • Tsutomu Kobayashi
    • 1
  • Shinichi Fuchida
    • 2
  • Mio Yamamoto-Sugitani
    • 1
  • Muneo Ohshiro
    • 1
  • Yuji Shimura
    • 1
  • Shinsuke Mizutani
    • 1
  • Hisao Nagoshi
    • 1
  • Nana Sasaki
    • 1
  • Ryuko Nakayama
    • 1
  • Yoshiaki Chinen
    • 1
  • Natsumi Sakamoto
    • 1
  • Hitoji Uchiyama
    • 1
  • Yosuke Matsumoto
    • 1
  • Shigeo Horiike
    • 1
  • Chihiro Shimazaki
    • 2
  • Junya Kuroda
    • 1
  • Masafumi Taniwaki
    • 1
  1. 1.Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of MedicineKyotoJapan
  2. 2.Department of HematologyKyoto Social Insurance HospitalKyotoJapan

Personalised recommendations